CLSN Celsion Dashboard

Celsion Corp . is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Company profile

Ticker

CLSN

Exchange

NASDAQ

Website

celsion.com/

CEO

Michael Tardugno

Incorporated

Delaware

Location

New Jersey

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

CHEUNG LABORATORIES INC

SEC CIK

0000749647

Corporate docs

Articles of Incorporation & Bylaws

IRS number

521256615

CLSN stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Celsion's Ovarian Cancer Immunotherapy Shows 41% Improvement In R0 Resection Rates

1 Apr 21

Celsion Says Poster On Co's Phase I/II OVATION 2 Study Presented At Society Of Gynecologic Oncology Virtual Annual Meeting On Women's Canver

1 Apr 21

Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that a poster highlighting the Company's ongoing Phase I/II OVATION 2

Why VTSI Stock AND CLSN Stock Are Trading Lower Today

31 Mar 21

Virtra Inc (NASDAQ: VTSI) shares are trading lower by 22% Wednesday after the company priced a registered direct offering at $6 per share.

12 Health Care Stocks Moving In Wednesday's Intraday Session

31 Mar 21

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

31 Mar 21

Press releases

Pro users get this 30m faster

CELSION CORPORATION ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING

5 Apr 21

Lawrenceville, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) ("Celsion" or the "Company"), today announced the closing of its previously announced registered direct offering of 11,538,462

Celsion Corp. to Host Earnings Call

19 Mar 21

NEW YORK, NY / ACCESSWIRE / March 19, 2021 / Celsion Corp. (NASDAQ:CLSN) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 19, 2021 at 11:00 AM Eastern Time.To

Celsion Corporation Reports 2020 Financial Results and Provides Business Update

19 Mar 21

Entered 2021 with a Focus on Cancer Immunotherapy and Next-Generation Infectious Vaccines and a Strong Balance Sheet Conference Call Begins at 11:00 a.m. Eastern Time Today LAWRENCEVILLE, N.J.,

Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021

12 Mar 21

Poster on Celsion Corporation's Phase I/II OVATION 2 Study to be Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women's Cancer

2 Mar 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

19 Mar 21

12 Apr 21

31 Dec 21

Financial summary

Financial statements Chart CLSN financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Celsion earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	17.16M	17.16M	17.16M	17.16M	17.16M	17.16M
Cash burn (monthly)	391.85K	(positive/no burn)	1.6M	1.54M	1.24M	1.3M
Cash used (since last report)	1.34M	n/a	5.46M	5.26M	4.25M	4.45M
Cash remaining	15.83M	n/a	11.7M	11.9M	12.91M	12.72M
Runway (months of cash)	40.4	n/a	7.3	7.7	10.4	9.8

Beta Read what these cash burn values mean

Recent insider trades

CLSN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
19 Mar 21	Chow Pok Yu Augustine	Option to Purchase Celsion Corporation Common Stock Celsion Corporation Common Stock	Grant	Aquire A	No	No	2.24	40,000	89.6K	183,689
19 Mar 21	Hooper Robert W	Option to Purchase Celsion Corporation Common Stock Celsion Corporation Common Stock	Grant	Aquire A	No	No	2.24	40,000	89.6K	179,737
19 Mar 21	Fritz Frederick J.	Option to Purchase Celsion Corporation Common Stock Celsion Corporation Common Stock	Grant	Aquire A	No	No	2.24	40,000	89.6K	180,118
19 Mar 21	Braun Donald P	Option to Purchase Celsion Corporation Common Stock Celsion Corporation Common Stock	Grant	Aquire A	No	No	2.24	40,000	89.6K	151,357
19 Mar 21	Voss Andreas	Option to Purchase Celsion Corporation Common Stock Celsion Corporation Common Stock	Grant	Aquire A	No	No	2.24	40,000	89.6K	151,357

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

CLSN institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	3	EXIT
Opened positions	0	0
Closed positions	3	0	NEW
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	108	EXIT
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change
Old Second National Bank Of Aurora	0	-50	EXIT
Arkadios Wealth Advisors	0	-43	EXIT
Emerald Advisers	0	-15	EXIT

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Codiak Biosciences

Management Discussion

Comparison of Fiscal Year Ended December 31, 2020 and Fiscal Year Ended December 31, 2019.
For the year ended December 31, 2020, our net loss was $21.5 million compared to a net loss of $16.9 million for the year ended December 31, 2019. The Company recognized $1.85 million and $1.82 million in tax benefits from the sale of its New Jersey net operating losses under the Technology Business Tax Certificate Program in each of the fourth quarters of 2020 and 2019, respectively. With $17.2 million in cash and cash equivalents, coupled with approximately $43 million of gross proceeds received from the sale of equity in the first quarter of 2021 and up to $1.85 million in expected proceeds from the sale of the State of New Jersey net operating losses it applied for in 2020, the Company believes it has sufficient capital resources to fund its operations through 2023.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Abbott, abundance, admitting, advisor, AKS, Alba, Allied, Altium, Alto, AMEDIX, amenable, Amersham, analyzing, Anthra, antibody, antigen, Arizona, assumption, Asta, AstraZeneca, attendance, attended, attending, Ayrton, bachelor, backdating, Basel, Bausch, Bayer, behavior, Behring, Biden, Bill, biographical, biology, Biomedical, Biomira, biopharma, bioterrorism, bladder, Boehringer, bold, Bonaventure, book, boost, boundary, Box, Brazil, breadth, Broadway, Brookline, brought, Brunswick, built, calendar, caption, captioned, career, carefully, Caribbean, carrier, cast, Cayman, Centocor, CEO, certified, certify, CFO, chain, Chicago, CIC, circumstance, clarification, claw, COBRA, Coleman, column, COMP, compatible, concept, conduit, confluence, constantly, constitutionality, constructively, contemplated, content, contest, CRADA, crossed, CSL, cum, CVI, cyclophosphamide, Cytogen, Dassault, dealer, delegate, delegated, delegation, demographic, denominated, deployment, detriment, diagnostic, dictating, Diego, disability, discharging, disregarding, dissolution, distancing, Dkt, doctoral, dollar, double, dozen, Dutch, earliest, easily, economy, eighteen, emphasizing, engineering, entry, eventual, eventually, evolutionary, exacerbate, excessive, excise, excitement, exciting, excusing, expressly, extinguishment, faith, fault, fellow, Fidler, FL, Floor, footnote, forensic, founder, Francisco, freedom, frozen, Fundacao, GeneMedicine, GenVec, George, Getulio, GmbH, GP, graduate, Grand, guideline, Hamburg, Harmony, Harvard, heading, hearing, helper, Hoffmann, House, household, Houston, humoral, immunology, Importantly, impressive, IMS, incumbent, inflammatory, insider, Insight, Inspector, intradermally, intramuscularly, intratumoral, invoiced, ITT, Japanese, Jessen, job, jointly, Joseph, judgement, justify, Kaisun, KGA, Khatri, Kobinger, laude, leadership, Legislature, lender, lent, liaison, lifetime, likelihood, Lincoln, linked, literacy, Lomb, London, LP, LPC, lump, Magnetic, Mannheim, marginally, Marine, Martin, Master, MBA, mBC, Medica, Medidata, Mercer, Merck, Meridian, merit, MFN, MFS, Microbiology, mimic, misleading, mitomycin, monotherapy, monovalent, motivate, mouse, MSc, multifunctional, multiplying, multitude, multivalent, mutation, mutational, Mylan, narrative, Nest, NeuroDx, neurosurgery, neutralizing, ninety, noncash, nonrenewal, Novavax, nuclear, nucleocapsid, NY, occasional, Ohio, opposed, opsonization, organizational, orientation, Outboard, outright, Overview, owner, pancreatic, PanDox, parallel, pathogen, Paulo, Paycheck, payroll, pecuniary, peer, pension, people, Pfizer, Pharma, philosophy, PLACCINE, plaintiff, pledging, Plough, podiatric, polymeric, postdoctoral, PPP, premedical, pro, promissory, promptly, propensity, properly, prophylactic, proportionate, prudent, purview, quantify, Radford, rata, ratification, reapplied, reappointed, reassessed, reconsideration, redoubling, regain, regained, Regression, relaying, renamed, renegotiate, repaid, repayment, reposition, resignation, Resonance, retention, retired, retirement, retroactive, revolutionize, Roche, rollout, routinely, running, Rush, Sandoz, Sao, Sarnoff, SBA, SCA, Schering, science, Segregated, sequence, Serono, Shortly, Silicon, simple, sliding, Society, Songbird, sound, sounding, spanning, Spar, SPC, Spike, spun, Squibb, staffing, staggered, stake, Sterling, stimulate, subcutaneously, successor, sum, summa, Super, surface, survey, tactical, Taiho, talent, talented, taxation, tenure, tool, Town, traditional, TSX, twelfth, twenty, Ugland, undergraduate, underway, unexercised, unprecedented, unregistered, unrestricted, untrue, unusual, unvested, uptake, upward, urge, urgent, USA, vacancy, vaccine, Valeo, Valley, vast, vigorously, vii, virtual, vote, voted, voting, VP, Waterhouse, web, welfare, Wesley, West, whatsoever, William, Winthrop, yearly, York, ZLB

Removed: Argentina, ATM, balanced, BCNU, brain, Bulgaria, CA, Cantor, CCNU, clearer, collected, conferring, confirming, Croatia, cumulated, Czech, Daegu, Denmark, deposited, dividend, dwell, enabling, escalating, Estonia, examined, exempt, Finland, Fitzgerald, formal, Gastroenterology, Greece, Hepatology, hoc, Hungary, incremental, Ireland, Israel, Korea, Kyungpook, largest, Latvia, launched, Lithuania, maker, Malta, matrix, mild, minimizing, modeling, OfferingSM, pegylation, perpetual, persuasive, Peru, Poland, Portugal, preferentially, presence, principle, progressive, prompted, radio, readout, registrational, Republic, Romania, Russia, simulation, Singapore, Slovakia, Slovenia, SM, split, sRFA, strongly, suffering, suggest, Sweden, Taiwan, Tak, unpredictable, unresectable, Vietnam, Won, write, Young, Zealand

From filing 10-K 2020 FY